본문 바로가기

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
BMC CANCER19(1) · 2019
피인용
Web of Science 21Scopus 29
FWCI (Scopus)
0.71
JCR IF
JCR 2018 2.933
ISSN
1471-2407

저자

  1. Kim, Seok Jin제1저자0000 0001 2181 989X grid.264381.a Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine 81 Irwon-ro, Gangnam-gu Seoul 06351 South Korea
  2. Yoon, Dok Hyun0000 0004 0533 4667 grid.267370.7 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea
  3. Kang, Hye Jin0000 0000 9489 1588 grid.415464.6 Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences Seoul South Korea
  4. Hong, Jung Yong0000 0004 0533 4667 grid.267370.7 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea
  5. Lee, Ho Sup0000 0004 0647 1110 grid.411145.4 Department of Internal Medicine, Kosin University Gospel Hospital Busan South Korea
  6. Oh, Sung Yong0000 0001 2218 7142 grid.255166.3 Department of Internal Medicine, Dong-A University College of Medicine Busan South Korea
  7. 신호진0000 0000 8611 7824 grid.412588.2 Department of Internal Medicine, Pusan National University Hospital Busan South Korea
  8. Kong, Jee Hyun0000 0004 0647 3124 grid.464718.8 Department of Internal Medicine, Wonju Severance Christian Hospital Wonju South Korea
  9. Yi, Jun Ho0000 0004 0647 4960 grid.411651.6 Department of Internal Medicine, Chung-Ang University Hospital Seoul South Korea
  10. Sakamoto, Kana0000 0001 0037 4131 grid.410807.a Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research Tokyo Japan
  11. Ko, Young Hyeh0000 0001 2181 989X grid.264381.a Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul South Korea
  12. Huh, Jooryung0000 0001 0842 2126 grid.413967.e Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea
  13. Lee, Seung-Sook0000 0000 9489 1588 grid.415464.6 Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences Seoul South Korea
  14. Takeuchi, Kengo0000 0001 0037 4131 grid.410807.a Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research Tokyo Japan
  15. Shin, Dong-Yeop0000 0001 0302 820X grid.412484.f Department of Internal Medicine, Seoul National University Hospital Seoul South Korea
  16. Suh, Cheolwon0000 0004 0533 4667 grid.267370.7 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea
  17. Kim, Won Seog교신저자0000 0001 2181 989X grid.264381.a Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine 81 Irwon-ro, Gangnam-gu Seoul 06351 South Korea

초록

© 2019 The Author(s).Background: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. Methods: Relapsed or refractory patients with HL or PMBCL were eligible for this study, and JAK2 amplification was assessed by fluorescence in situ hybridization. Ruxolitinib was administered orally at a dose of 20 mg twice daily for a 28-day cycle. Treatment was continued for up to 16 cycles or until progressive disease or intolerability. The primary objective was to assess the overall disease control rate comprising complete response (CR), partial response (PR), or stable disease (SD). Results: We analyzed 13 HL patients and six PMBCL patients. All responders (one CR, five PR, and one SD) had HL whereas all cases of PMBCL progressed after first or second cycle. The disease control rate for HL was 54% (7/13) with median response duration of 5.6 months. JAK2 amplification was present in six of nine patients tested (four HL, two PMBCL), and three of these HL patients showed PR (n = 2) or SD (n = 1). None of the three HL patients shown to not have JAK2 amplification responded to ruxolitinib. Most treatment-related adverse events were grade 1 or 2 and manageable. Conclusions: Ruxolitinib has single-agent activity against HL but does not act against PMBCL with or without JAK2 amplification. Trial registration: The study population was patients who had relapsed or refractory HL or PMBCL, and patients were registered for our pilot study after providing written informed consent between November 2013 and November 2015 (CilinicalTrials.gov: NCT01965119).

키워드

Hodgkin lymphomaJAK2Mediastinal large B-cell lymphomaRuxolitinib

식별자

Scopus EID
2-s2.0-85074741985
WoS UID
000495588300001